Nursing care
Anthracyclines: cardiotoxicity monitoring, vesicant safety and red urine teaching
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Anthracyclines such as doxorubicin damage cancer cell DNA but can also injure heart muscle, with risk rising as the lifetime cumulative dose grows. Nurses confirm a baseline ejection fraction, track cumulative dose and heart failure signs, treat the drug as a vesicant that can destroy tissue if it leaks, and teach that red urine for a day or two is expected.
Why anthracyclines carry their own risks
Doxorubicin and related anthracyclines insert themselves into DNA and interfere with topoisomerase II, an enzyme cells need to copy DNA, which kills rapidly dividing cells. The process also produces free radicals, which is thought to contribute to injury in heart muscle. General chemotherapy precautions still apply, but this class adds three particular concerns: the heart, the vein and the urine colour.
The doxorubicin label carries boxed warnings for cardiomyopathy, secondary leukaemia, severe tissue necrosis with extravasation, and severe myelosuppression. Neutropenia, mouth sores, nausea and hair loss are expected chemotherapy effects. The anthracycline-specific skill is recognising heart and vein problems early and knowing they can appear long after the infusion.
Cardiotoxicity and cumulative dose
Anthracycline cardiomyopathy can present during treatment or years later, and the label shows heart failure risk climbing as the total lifetime dose rises. Risk is higher with previous chest or mediastinal radiation, existing heart disease, older age, and other cardiotoxic drugs such as trastuzumab or cyclophosphamide. The label advises assessing left ventricular ejection fraction before and during treatment.
The nurse checks that a baseline echocardiogram or nuclear scan is documented, that the running cumulative dose is recorded, and that a follow-up scan is done when due. Before each cycle, ask about breathlessness, reduced exercise tolerance, orthopnoea, ankle swelling or palpitations, and weigh the patient. New findings are reported before the dose is given, not after. Dexrazoxane may be prescribed as a cardioprotectant in specific situations.
Vesicant precautions and extravasation
A vesicant causes blistering and tissue death if it escapes the vein. Doxorubicin must never be given by the intramuscular or subcutaneous route. Many units use central venous access, and with peripheral lines the nurse confirms blood return before and during administration and watches the site closely. The patient is taught to report burning, stinging or swelling immediately.
If extravasation is suspected, the nurse stops the infusion straight away, notifies the prescriber and follows the unit extravasation policy, which sets out the local steps and any antidote. The site is documented and reviewed because necrosis can progress over days, and hand or arm injuries may need surgical review.
Red urine, blood counts and patient teaching
Doxorubicin colours urine red for one to two days after a dose. Teaching this in advance prevents panic and unnecessary emergency visits, but the patient also needs to know that true bleeding is possible when platelets are low. Ask the patient to report red urine that lasts beyond the expected window, clots, or bleeding elsewhere such as gums or stools.
Myelosuppression makes infection teaching essential: report fever, chills, sore throat or a cough without delay. Tumour lysis syndrome can occur with rapidly responsive cancers, so uric acid, electrolytes and creatinine may be monitored. The label advises effective contraception for both sexes and notes that vaccines should be discussed with the oncology team. Shortness of breath and leg swelling need prompt reporting.
Working a hypothetical anthracycline scenario
Imagine a patient due for a doxorubicin cycle who reports needing three pillows to sleep and new ankle swelling, with weight up since the last visit. The options are to start the infusion and report afterwards, give a diuretic from the as-needed list, hold the infusion and notify the prescriber, or reassure the patient that fluid retention is expected with chemotherapy.
Holding the infusion and notifying the prescriber is the best response because orthopnoea, oedema and weight gain may signal anthracycline cardiomyopathy, and a further dose could worsen it. Starting first adds dose to a possibly failing heart, a diuretic treats a symptom without evaluation, and reassurance dismisses a warning sign. This is a hypothetical study scenario.
Sources and further reading
DailyMed: Doxorubicin hydrochloride injection prescribing information. Mechanism, boxed warnings, cumulative-dose cardiomyopathy, risk factors, ejection fraction assessment, dexrazoxane, extravasation, red urine, tumour lysis and contraception.
MedlinePlus: Doxorubicin injection. Patient teaching on red urine, heart failure symptoms, injection site reactions and infection signs.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our med-surg practice questions are the closest set to what this page covers.
One question from the med-surg set
A client with chronic obstructive pulmonary disease has an oxygen saturation of 88% on 2 L/min via nasal cannula and is alert with no distress. What should the nurse do first?
Rationale
In COPD a saturation of 88–92% is the therapeutic target, not an emergency, and this client is alert with no distress. The first action is the independent nursing intervention that is least invasive and most likely to help: sit them up and reassess. Turning the oxygen up to 6 L/min risks blunting the hypoxic drive, and calling rapid response or drawing an ABG escalates ahead of an assessment you have not finished.
Answer: B
Common questions
Is red urine after doxorubicin a sign of bleeding?
Usually not. Doxorubicin turns urine red for about one to two days after a dose. Colour lasting longer, clots or other bleeding signs should be reported because low platelets can cause true bleeding.
Why does the cumulative dose of doxorubicin matter?
Heart failure risk rises as the lifetime total grows, and damage may appear years later. Nurses help track the running total and confirm cardiac function checks are done.
What is the first action if a doxorubicin infusion site starts burning?
Stop the infusion immediately, then follow the extravasation protocol and notify the prescriber. Doxorubicin is a vesicant that can cause severe tissue necrosis.
More on med-surg